An Investigator’s Brochure (IB) is one of the most important documents supporting the safe and informed conduct of clinical trials. It brings together relevant clinical and nonclinical information about an investigational product so that investigators can understand its characteristics, potential risks, and appropriate precautions.

For sponsors, preparing an effective IB is not simply a matter of collecting available study data. The information must be presented accurately, objectively, and in a way that helps investigators understand the overall benefit-risk profile of the investigational product. FDA regulations and guidance establish important expectations for the content and ongoing maintenance of the document.

Why Is the Investigator’s Brochure Important?

The IB provides investigators with information relevant to the study of an investigational drug in human subjects. It is intended to help investigators understand the scientific and clinical context of the product and recognize important safety considerations during the trial. FDA also recognizes the IB as an important source for determining whether a suspected adverse reaction is unexpected for IND safety reporting purposes.

For this reason, the document should provide a balanced presentation of relevant information rather than functioning as promotional material. A well-prepared FDA Investigator Brochure should communicate both favorable and unfavorable findings in an appropriate scientific and regulatory context.

What Does FDA Require in an Investigator’s Brochure?

Under 21 CFR 312.23(a)(5), an IB should include specific information about the investigational drug. This includes a brief description of the drug substance and formulation, together with the structural formula when known.

The document should summarize pharmacological and toxicological effects observed in animals and, where known, in humans. It should also address pharmacokinetic and biological disposition information from animal studies and human experience when available.

Previous human experience should be summarized, including relevant safety and effectiveness information from clinical studies. Published articles may be included when they provide useful supporting information.

The IB should also describe possible risks and side effects based on prior experience with the investigational drug or related drugs, together with relevant precautions and special monitoring requirements.

Presenting Clinical Risk Information

One of the most important aspects of Investigator’s Brochure FDA requirements is the appropriate presentation of clinical risk information.

FDA recommends that the IB specifically and accurately identify adverse events observed with the investigational drug when a causal relationship is suspected or confirmed. Events that commonly occur with the drug class or could reasonably be predicted from the product’s pharmacological properties may also be important to include, even if they have not yet been observed with the investigational product.

At the same time, sponsors should avoid filling the IB with adverse events that are unlikely to have been caused by the drug. Excessive or poorly evaluated information can make clinically meaningful risks more difficult for investigators to recognize.

The Importance of Tone and Scientific Balance

The tone of an IB is particularly important. The document should communicate scientific information objectively and avoid language that exaggerates potential benefits or minimizes known or potential risks.

Sponsors should carefully distinguish between established findings, emerging evidence, hypotheses, and areas where information remains limited. Statements should be supported by appropriate data and references.

A balanced tone is particularly important because the IB is intended to educate investigators rather than promote the investigational product. FDA’s guidance emphasizes accurate presentation of clinical risk information, making objective language an important part of regulatory-quality Investigator Brochure writing.

Structuring and Formatting the IB

FDA does not prescribe one mandatory format for every Investigator’s Brochure. The agency accepts a variety of formats, provided that the required information is appropriately presented.

Regardless of the specific format selected, the document should be logically organized and easy for investigators to navigate. Important safety information should not be buried within lengthy technical sections.

Clear headings, consistent terminology, appropriate references, tables where useful, and an effective presentation of clinical and nonclinical findings can improve the usability of the document.

The formatting should support the purpose of the IB: helping investigators quickly locate information that may affect the safe conduct of the clinical investigation.

Keeping the Investigator’s Brochure Current

An IB is a living regulatory document. As the development program progresses, new clinical and nonclinical information may become available and should be evaluated for its potential impact on the document.

Under 21 CFR 312.55, sponsors must keep participating investigators informed about new observations concerning the investigational drug, particularly information related to adverse effects and safe use. This can be accomplished through revised IBs, publications, reports, letters, or other appropriate communications.

FDA guidance also recommends updating the IB on an ongoing basis when important new safety information becomes available. Some information may require prompt communication rather than waiting for a routine document revision.

Consistency With Other Clinical Trial Documents

The IB should not be developed in isolation. Sponsors should evaluate its consistency with other important clinical and regulatory documents, including the clinical protocol, informed consent materials, safety reporting information, and relevant regulatory submissions.

Differences in safety terminology, risk descriptions, dosing information, or other important product information can create confusion for investigators and may raise regulatory concerns.

A structured cross-functional review involving clinical, medical, pharmacovigilance, nonclinical, regulatory, and medical writing teams can help identify inconsistencies before the IB is finalized.

Common Problems in Investigator’s Brochures

FDA review concerns can arise when an IB is overly promotional, fails to adequately communicate risks, contains outdated information, or presents scientific findings without sufficient context.

Another common problem is excessive information that makes the document difficult for investigators to use. The objective should not be to include every piece of available data, but to provide information that is relevant and useful for understanding the investigational product and its risks.

The FDAMap webinar specifically highlights common errors, FDA concerns, writing style, tone, citations, formatting, and approaches for presenting positive, negative, and neutral information in an appropriate balance.

Building an FDA-Ready Investigator’s Brochure

Developing a high-quality IB requires a controlled process. Sponsors should establish clear responsibilities for drafting, scientific review, medical review, regulatory review, quality review, approval, version control, distribution, and revision.

The review process should also evaluate whether newly available safety information changes the product’s overall risk profile or requires communication to investigators.

Training personnel involved in IB development is equally valuable. Medical writers and regulatory professionals should understand not only the required content but also how FDA expects scientific and safety information to be presented.

Conclusion

An Investigator’s Brochure is a critical clinical development document that supports investigator understanding, participant safety, and regulatory compliance. Meeting Investigator’s Brochure FDA requirements requires careful attention to content, scientific accuracy, risk communication, tone, formatting, references, and ongoing updates.

A strong IB should be informative without becoming promotional, comprehensive without becoming unnecessarily difficult to use, and current throughout the clinical development program.

For sponsors, medical writers, clinical research professionals, regulatory affairs teams, and quality professionals, understanding effective Investigator Brochure writing can help strengthen document quality and reduce common regulatory concerns.

FDAMap’s webinar “FDA Rules for the Content, Tone and Format of an Investigator’s Brochure” provides practical guidance on IB content, writing style, tone, formatting, common FDA findings, review practices, and strategies for presenting information in a balanced and regulatory-appropriate manner.